In the first half of the year, the pharmaceutical and biological sectors rode through the dust, with 58 companies reporting earnings growth.

Wind statistics show that as of August 19, 822 companies in the two cities have officially disclosed their semi-annual reports, of which 477 home-based net profit increased year-on-year, accounting for more than 58%;
In terms of industry, the pharmaceutical and biological sector in the first half of the year, a total of 58 companies profit growth, and in the top 10 companies in the performance growth rate, Zhende Medical, Oriental Bio, two companies affiliated in the field of pharmaceutical biology on the list.
, a medical dressing industry company, disclosed its 2020 half-yearly report on the afternoon of August 17.
first half of this year, Zhende Medical achieved operating income of about RMB3.82 billion, up 401.24% YoY, and net profit attributable to shareholders of listed companies was RMB989 million, up 1544.74% YoY.
the first half of this year, its epidemic prevention supplies achieved sales revenue of 2.648 billion yuan.
Zhende Medical said that the company's first-half operating results increased significantly from a year earlier, mainly due to the impact of special periods, the company's epidemic prevention products sales increased significantly, the acquisition of the United Kingdom Rocialle Healthcare Limited 55% of the company's consolidated statements and the company excluded epidemic prevention products outside the business revenue growth.
, in addition to the good results, Zhende Medical's share price trend this year also followed.
Choice Financial Terminal data show that Zhende Medical's total market value has increased from 3,045 million yuan at the end of 2019 to 10,251 million yuan at the end of the first half of 2020, and its total market value has increased by about 7,206 million yuan, or about 236.65 percent, in the first half of the year.
ended on August 17th, Zhende Medical's rise and fall so far this year was 30 days.
according to incomplete statistics, Zhende Medical has disclosed 11 stock trading abnormal volatility announcements so far this year.
Bio is a company engaged in in-body diagnostic product development, production and sales, its first half revenue, net profit growth. According to the company's 2020 semi-annual report released before
, the company achieved operating income of 828 million yuan in the first half of 2020, up 388.05 percent year-on-year, and net profit attributable to shareholders of listed companies was 524 million yuan, up 1477.45 percent year-on-year.
said revenue growth during the reporting period was mainly due to a significant increase in sales of related testing products.
In the view of industry people, the first half of the pharmaceutical and biological sector ushered in a sharp rise in half-yearly results, mainly in recent years with the pharmaceutical policy pressure and the company's valuation is gradually digested, industry leaders gradually get rid of the impact of policy, performance began to shine.
, coupled with the impact of this year's special period, the demand for medical drugs and equipment increased significantly, leading to the growth of half-year results.
In the medium to long term, the industry generally believes that the current pharmaceutical and biological sector interim results are better, but the overall differentiation of the industry is obvious, especially the recent stock price surge and valuation rise too fast bio-vaccine concept ushered in a continuous adjustment, driving the overall pharmaceutical sector correction.
, the division in the pharmaceutical sector will intensify, with the industry suggesting investors need to choose a "good track".
vaccines, medical devices, innovative drugs and other sub-sectors, the demand side of the long-term certainty is relatively high, worthy of attention.
Is mainly based on the following thinking: in the volume procurement, consistency evaluation, encourage the implementation of innovative drugs and other policies, innovative drugs become the development trend of the pharmaceutical industry, worthy of long-term optimism, and with the upgrading of people's consumption, the enhancement of health care awareness, as well as the number of chronic diseases under the aging, coupled with the future domestic investment in the field of health care, vaccines, medical devices and other sub-sectors will also usher in opportunities.
.